Non-lipid effects of rosuvastatin-fenofibrate combination therapy in high-risk Asian patients with mixed hyperlipidemia

Atherosclerosis

Volumn 221, Issue 1, 2012, Pages 169-175

  Lee, Sang Hak ^a   Cho, Kyoung Im ^b   Kim, Jang Young ^c   Ahn, Young Keun ^d   Rha, Seung Woon ^e   Kim, Yong Jin ^f   Choi, Yun Seok ^g   Choi, Si Wan ^h   Jeon, Dong Woon ⁱ   Min, Pil Ki ^a   Choi, Dong Ju ^j   Baek, Sang Hong ^k   Kim, Kwon Sam ^l   Byun, Young Sup ^m   Jang, Yangsoo ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Maryknoll Hospital   (South Korea)

^c Yonsei University Wonju College of Medicine   (South Korea)

^d Chonnam National University Medical School   (South Korea)

^e Korea University College of Medicine   (South Korea)

^f Seoul National University College of Medicine   (South Korea)

^g The Catholic University of Korea   (South Korea)

^h Chungnam National University   (South Korea)

ⁱ National Health Insurance Corporation   (South Korea)

^j Seoul National University Bundang Hospital   (South Korea)

^k The Catholic University of Korea   (South Korea)

^l Kyung Hee University Hospital   (South Korea)

^m Inje University College of Medicine   (South Korea)

more..

Author keywords

Asia; Creatine kinase; Fenofibrate; Rosuvastatin; Safety

Indexed keywords

FENOFIBRATE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; ROSUVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASIAN; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIET; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; KIDNEY DISEASE; LEUKOCYTE COUNT; LIFESTYLE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUSCLE DISEASE; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME; UREA NITROGEN BLOOD LEVEL;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD UREA NITROGEN; CARDIOVASCULAR DISEASES; CREATININE; DRUG COMBINATIONS; DRUG-INDUCED LIVER INJURY; ENZYMES; FEMALE; FENOFIBRATE; FLUOROBENZENES; HEMOGLOBINS; HOMOCYSTEINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS; LIPIDS; LIVER; MALE; MIDDLE AGED; MUSCLE, SKELETAL; PATIENT SELECTION; PYRIMIDINES; REPUBLIC OF KOREA; RHABDOMYOLYSIS; RISK ASSESSMENT; RISK FACTORS; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84862806187     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.12.042     Document Type: Article

References (34)

1. Jun M., Foote C., Lv J., et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010, 375:1875-1884.
2. Saha S.A., Arora R.R. Hyperlipidaemia and cardiovascular disease: do fibrates have a role. Curr Opin Lipidol 2011, 22:270-276.
3. Keech A.C., Mitchell P., Summanen P.A., et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007, 370:1687-1697.
4. Davis T.M., Ting R., Best J.D., et al. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia 2011, 54:280-290.
5. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010, 363:233-244. The ACCORD Study Group and ACCORD Eye Study Group.
6. Pierce L.R., Wysowski D.K., Gross T.P. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990, 264:71-75.
7. Farnier M. Safety review of combination drugs for hyperlipidemia. Expert Opin Drug Saf 2011, 10:363-371.
8. Jones P.H., Davidson M.H. Reporting rate of rhabdomyolysis with fenofibrate+statin versus gemfibrozil+any statin. Am J Cardiol 2005, 95:120-122.
9. Martin P.D., Dane A.L., Schneck D.W., Warwick M.J. An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. Clin Ther 2003, 25:459-471.
10. Keech A., Simes R.J., Barter P., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005, 366:1849-1861.
11. Ginsberg H.N., Elam M.B., et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010, 362:1563-1574. The ACCORD Study Group.
12. Reiner Z., Catapano A.L., De Backer G., et al. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011, 32:1769-1818.
13. Alsheikh-Ali A.A., Ambrose M.S., Kuvin J.T., Karas R.H. The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. Circulation 2005, 111:3051-3057.
14. Grundy S.M. The issue of statin safety: where do we stand. Circulation 2005, 111:3016-3019.
15. Lee E., Ryan S., Birmingham B., et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 2005, 78:330-341.
16. Matsuzawa Y., Kita T., Mabuchi H., et al. Sustained reduction of serum cholesterol in low-dose 6-year simvastatin treatment with minimum side effects in 51,321 Japanese hypercholesterolemic patients. Circ J 2003, 67:287-294.
17. Koba S., Sasaki J. Treatment of hyperlipidemia from Japanese evidence. J Atheroscler Thromb 2006, 13:267-280.
18. Durrington P.N., Tuomilehto J., Hamann A., Kallend D., Smith K. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia. Diabetes Res Clin Pract 2004, 64:137-151.
19. Davidson M.H., Rooney M.W., Drucker J., Eugene Griffin H., Oosman S., Beckert M. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study. Clin Ther 2009, 31:2824-2838.
20. Jones P.H., Davidson M.H., Kashyap M.L., et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study. Atherosclerosis 2009, 204:208-215.
21. Roth E.M., Rosenson R.S., Carlson D.M., et al. Efficacy and safety of rosuvastatin 5mg in combination with fenofibric acid 135mg in patients with mixed dyslipidemia - a phase 3 study. Cardiovasc Drugs Ther 2010, 24:421-428.
22. Rosenson R.S., Carlson D.M., Kelly M.T., et al. Achievement of lipid targets with the combination of rosuvastatin and fenofibric Acid in patients with type 2 diabetes mellitus. Cardiovasc Drugs Ther 2011, 25:47-57.
23. Foucher C., Brugere L., Ansquer J.C. Fenofibrate, homocysteine and renal function. Curr Vasc Pharmacol 2010, 8:589-603.
24. Playford D.A., Watts G.F., Best J.D., Burke V. Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus. Am J Cardiol 2002, 90:1254-1257.
25. Reyes-Soffer G., Rondon-Clavo C., Ginsberg H.N. Combination therapy with statin and fibrate in patients with dyslipidemia associated with insulin resistance, metabolic syndrome and type 2 diabetes mellitus. Expert Opin Pharmacother 2011, 12:1429-1438.
26. Broeders N., Knoop C., Antoine M., Tielemans C., Abramowicz D. Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent. Nephrol Dial Transplant 2000, 15:1993-1999.
27. Bajaj M., Suraamornkul S., Hardies L.J., Glass L., Musi N., DeFronzo R.A. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus. Diabetologia 2007, 50:1723-1731.
28. Perreault L., Bergman B.C., Hunerdosse D.M., Howard D.J., Eckel R.H. Fenofibrate administration does not affect muscle triglyceride concentration or insulin sensitivity in humans. Metabolism 2011, 60:1107-1114.
29. Bays H.E., Roth E.M., McKenney J.M., et al. The effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia. Diabetes Care 2010, 33:2113-2116.
30. Krysiak R., Gdula-Dymek A., Bachowski R., Okopien B. Pleiotropic effects of atorvastatin and fenofibrate in metabolic syndrome and different types of pre-diabetes. Diabetes Care 2010, 33:2266-2270.
31. Roberts W.C. Safety of fenofibrate - US and worldwide experience. Cardiology 1989, 76:169-179.
32. Ames P.R. Simvastatin-induced thrombocytopaenia: a further case and a brief on its clinical relevance. Ann Hematol 2008, 87:773-774.
33. Vrettos I., Papageorgiou S., Economopoulou C., et al. Rosuvastatin-induced thrombocytopenia. South Med J 2010, 103:676-678.
34. The AIM-HIGH Investigators Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011, 365:2255-2267.